News | July 22, 2023
Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
This transformation will enable GE HealthCare to build a strong foundation for business growth
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Subscribe To Our Newsletter & Stay Updated
